Return to Listing

26 result(s) for Breast Cancer

PI Name Protocol # Title
Wei Huang IRB00004840 Quantitative Dynamic Contrast-Enhanced Breast MRI
Zahi Mitri IRB00006256 [Wake Forest IRB - IREx] I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Gordon Mills STUDY00016113 Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
Zahi Mitri STUDY00017461 [NCI CIRB] A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Jacqueline Vuky STUDY00017504 MonarchE: Protocol 13Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Rajan Kulkarni STUDY00017648 VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
Zahi Mitri STUDY00017887 A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Kerri Winters STUDY00018000 Exercising Together: A randomized controlled trial of partnered exercise training on the health of couples coping with cancer
Zahi Mitri STUDY00018504 A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
Zahi Mitri STUDY00019078 [NCI CIRB] S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Zahi Mitri STUDY00019830 A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 with Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
Christopher Ryan STUDY00019992 [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
Zahi Mitri STUDY00020112 Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Zahi Mitri STUDY00020440 A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies
Kiri Cook STUDY00020501 A Randomized Trial of Standard Verbal Counseling with or without a Pictorial Educational Tool to Reduce Psychological Morbidity in Women Receiving Breast Radiation Therapy
Zahi Mitri STUDY00021243 OHSU IIT: A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer
Zahi Mitri STUDY00021441 EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
Christopher Ryan STUDY00021677 [NCI CIRB] NCICOVID - NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Zahi Mitri STUDY00022179 The Breast Cancer Observational Study
Zahi Mitri STUDY00022191 A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)
Zahi Mitri STUDY00022225 A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer
Kiri Cook STUDY00022257 [NCI CIRB] MA.39 - TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
Zahi Mitri STUDY00022388 A Single Arm Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer
Zahi Mitri STUDY00022395 A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Stage II-III, Estrogen Receptor Positive, HER2-negative Breast Cancer (DARE)
Tom Beer STUDY00022989 Project Danube: Multi-Cancer and Comorbidity Blood Sample Collection for Cross-Reactivity Analysis for a Multiomics CRC Screening Test
Amy Ross STUDY00023183 Feasibility of substitution of virtual reality greenspace and volatile organic compound humidification to simulate the forest experience effects on immune system recovery.
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080